- Home
- BLDP vs ERAS Comparison
BLDP vs ERAS Comparison
Compare BLDP & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLDP
- ERAS
- Stock Information
- Founded
- BLDP 1979
- ERAS 2018
- Country
- BLDP Canada
- ERAS United States
- Employees
- BLDP N/A
- ERAS N/A
- Industry
- BLDP Industrial Machinery/Components
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- BLDP Energy
- ERAS Health Care
- Exchange
- BLDP Nasdaq
- ERAS Nasdaq
- Market Cap
- BLDP 368.8M
- ERAS 348.4M
- IPO Year
- BLDP 1995
- ERAS 2021
- Fundamental
- Price
- BLDP $1.42
- ERAS $1.57
- Analyst Decision
- BLDP Sell
- ERAS Strong Buy
- Analyst Count
- BLDP 11
- ERAS 6
- Target Price
- BLDP $1.71
- ERAS $4.83
- AVG Volume (30 Days)
- BLDP 9.0M
- ERAS 1.6M
- Earning Date
- BLDP 05-06-2025
- ERAS 05-13-2025
- Dividend Yield
- BLDP N/A
- ERAS N/A
- EPS Growth
- BLDP N/A
- ERAS N/A
- EPS
- BLDP N/A
- ERAS N/A
- Revenue
- BLDP $70,668,000.00
- ERAS N/A
- Revenue This Year
- BLDP $43.80
- ERAS N/A
- Revenue Next Year
- BLDP $25.81
- ERAS N/A
- P/E Ratio
- BLDP N/A
- ERAS N/A
- Revenue Growth
- BLDP N/A
- ERAS N/A
- 52 Week Low
- BLDP $1.00
- ERAS $1.01
- 52 Week High
- BLDP $3.00
- ERAS $3.45
- Technical
- Relative Strength Index (RSI)
- BLDP 58.59
- ERAS 62.94
- Support Level
- BLDP $1.24
- ERAS $1.26
- Resistance Level
- BLDP $1.49
- ERAS $1.47
- Average True Range (ATR)
- BLDP 0.09
- ERAS 0.14
- MACD
- BLDP -0.00
- ERAS 0.04
- Stochastic Oscillator
- BLDP 72.00
- ERAS 79.69
About BLDP Ballard Power Systems Inc.
Ballard Power Systems Inc is engaged in design, development, manufacture, sale and service of proton exchange membrane ("PEM") fuel cell products for a variety of applications, focusing on power products for bus, truck, rail, marine, stationary and emerging market (material handling, off-road and other) applications, as well as the delivery of services, including technology solutions, after sales services and training. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. Key geographical revenue is derived from Poland followed by United States, United Kingdom, and other countries.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.